[Cited FineTest ELISA Kit] Current Research on Lipid Nanoparticles for mRNA Delivery

FineTest ELISA kit contributes to the research on lipid nanoparticles for mRNA delivery. The immunoassay is designed to measure PEG-IgG and IgM level in serum.

Article Title: Albumin-recruiting lipid nanoparticle potentiates the safety and efficacy of mRNA vaccines by avoiding liver accumulation
Journal Title: Nature Materials
DOI: 10.1038/s41563-025-02284-w
IF: 38.5
PMID: 40750835

Abstract: The advent of mRNA vaccines represents a breakthrough in the realm of cancer therapy and the prevention of infectious disease. Nevertheless, traditional lipid nanoparticle (LNP)-based mRNA vaccines can accumulate in the liver post-intramuscular injection, posing a risk of hepatotoxicity and reducing efficacy. Here we develop an albumin-recruiting LNP system with high lymphatic drainage and no accumulation in hepatic tissue to potentiate the efficacy and safety of mRNA vaccines. We construct a library of ionizable lipids with albumin-binding capacity as alternatives to traditional polyethylene-glycol-conjugated lipid. We identify an Evans blue-modified lipid-based LNP (EB-LNP) formulation that shows high in vivo expression, albumin-facilitated transport through intramuscular lymphatic vessels to the lymph nodes, high internalization by dendritic cells and low penetration into intramuscular blood vessels, thereby avoiding liver accumulation. EB-LNP-based mRNA vaccines demonstrate excellent antitumour and antiviral efficacy, resulting in strong cellular and humoral immune responses, including the robust activation of cytotoxic T lymphocytes and production of neutralizing antibodies post-vaccination. Overall, this system shows promise as an effective and minimally toxic platform for the development of mRNA vaccines with high efficacy and safety.

Keywords: Nano Drug Delivery System, mRNA Delivery, Preclinical Research, mRNA Vaccine, Cancer Therapy, Infectious Disease, Nanomaterials

Immunoassay

Validated Image

Figure Source: Nat Mater. 2025 Aug 1. doi: 10.1038/s41563-025-02284-w.